Savant Capital LLC Has $1.46 Million Position in DaVita Inc. (NYSE:DVA)

Savant Capital LLC lessened its holdings in shares of DaVita Inc. (NYSE:DVA) by 3.9% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,730 shares of the company’s stock after selling 393 shares during the quarter. Savant Capital LLC’s holdings in DaVita were worth $1,455,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. Transcendent Capital Group LLC bought a new stake in shares of DaVita during the third quarter worth about $25,000. Blue Trust Inc. boosted its stake in DaVita by 56.4% during the 3rd quarter. Blue Trust Inc. now owns 330 shares of the company’s stock valued at $54,000 after purchasing an additional 119 shares during the last quarter. Quarry LP bought a new stake in DaVita during the 3rd quarter worth approximately $60,000. Versant Capital Management Inc lifted its holdings in shares of DaVita by 58.7% in the fourth quarter. Versant Capital Management Inc now owns 457 shares of the company’s stock valued at $68,000 after purchasing an additional 169 shares in the last quarter. Finally, Huntington National Bank boosted its position in shares of DaVita by 39.1% during the third quarter. Huntington National Bank now owns 768 shares of the company’s stock valued at $126,000 after buying an additional 216 shares during the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

DaVita Price Performance

Shares of NYSE DVA opened at $177.45 on Friday. The company has a market capitalization of $14.55 billion, a PE ratio of 19.14, a PEG ratio of 0.84 and a beta of 0.94. The company has a quick ratio of 1.33, a current ratio of 1.37 and a debt-to-equity ratio of 15.78. The stock’s 50 day moving average price is $161.47 and its 200-day moving average price is $157.25. DaVita Inc. has a twelve month low of $118.56 and a twelve month high of $179.60.

DaVita (NYSE:DVA) last posted its quarterly earnings data on Thursday, February 13th. The company reported $2.24 earnings per share for the quarter, topping the consensus estimate of $2.14 by $0.10. DaVita had a return on equity of 88.18% and a net margin of 6.53%. On average, equities analysts anticipate that DaVita Inc. will post 9.71 EPS for the current year.

Analysts Set New Price Targets

Separately, Barclays increased their price target on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, DaVita currently has a consensus rating of “Hold” and a consensus price target of $161.80.

DaVita Company Profile

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.